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Mitochondrial dysfunction accounts for a large group of inherited metabolic disorders most of which are due to
a dysfunctional mitochondrial respiratory chain (MRC) and, consequently, deficient energy production. MRC function
depends on the coordinated expression of both nuclear (nDNA) and mitochondrial (mtDNA) genomes. Thus,
mitochondrial diseases can be caused by genetic defects in either the mitochondrial or the nuclear genome, or in
the cross-talk between the two. This impaired cross-talk gives rise to so-called nuclear-mitochondrial intergenomic
communication disorders, which result in loss or instability of the mitochondrial genome and, in turn, impaired
maintenance of qualitative and quantitative mtDNA integrity. In children, most MRC disorders are associated with
nuclear gene defects rather than alterations in the mtDNA itself.
The mitochondrial DNA depletion syndromes (MDSs) are a clinically heterogeneous group of disorders with an
autosomal recessive pattern of transmission that have onset in infancy or early childhood and are characterized
by a reduced number of copies of mtDNA in affected tissues and organs. The MDSs can be divided into least four
clinical presentations: hepatocerebral, myopathic, encephalomyopathic and neurogastrointestinal. The focus of
this review is to offer an overview of these syndromes, listing the clinical phenotypes, together with their relative
frequency, mutational spectrum, and possible insights for improving diagnostic strategies.
Keywords: Mitochondrial DNA depletion syndrome, Mitochondrial myopathy, Mitochondrial encephalomyopathy,
Hepatocerebral syndrome, mtDNA, OxPhos, Alpers-Huttenlocher syndromeIntroduction
Mitochondria, present in almost all eukaryotic cells, are
dynamic cellular organelles specifically involved in the pro-
duction of cellular energy via the mitochondrial respiratory
chain (MRC) and the oxidative phosphorylation (OxPhos)
system. In addition to their most important function, ATP
production, mitochondria are involved in the regulation of
other cellular pathways such as calcium homeostasis, apop-
tosis and programmed cell death [1].
Mitochondrial disorders are a group of genetically and
phenotypically pleiomorphic disorders with an estimated
incidence of between 1:5,000 and 1:10,000 live births [2];* Correspondence: laura.vilarinho@insa.min-saude.pt; filippo3364@gmail.com
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unless otherwise stated.they are often attributable to OxPhos system dysfunc-
tion, which leads to a deficiency in ATP production.
The MRC is regulated through the interaction of two
physically and functionally separate genomes: the nuclear
DNA (nDNA) and the mitochondrial DNA (mtDNA) ge-
nomes. Of the estimated > 1000 proteins making up the
mitochondrial proteome [3] (see also http://www.broadin
stitute.org/pubs/MitoCarta/human.mitocarta.html), about
92 nDNA-encoded ones are the structural subunits
forming the five multiprotein complexes embedded in
the inner mitochondrial membrane. Human mtDNA
encodes 13 subunits of the OxPhos complex, two riboso-
mal RNA (rRNA) genes and 22 transfer RNA (tRNA)
genes, all of which are required for initiating protein
translation and synthesis [4]. Therefore, although human
mtDNA codes for the basic machinery of protein synthe-
sis, a number of nuclear-encoded factors (including the
enzymes for replication, repair and transcription) are also
needed to allow protein translation. This dependency liesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Nogueira et al. Italian Journal of Pediatrics 2014, 40:34 Page 2 of 10
http://www.ijponline.net/content/40/1/34at the heart of several recently recognized human diseases
that are characterized by secondary abnormalities of
mtDNA. Cross-talk between the nDNA and mtDNA
genomes is crucial for the maintenance of qualitative and
quantitative mtDNA integrity and for correct mitochon-
drial protein production. Multiple deletions, depletion,
or a combination of the two in critical tissues, are
“hallmarks” of disease conditions arising from disrupted
communication between these two genomes. Since a con-
gruous amount of mtDNA is required to produce the key
subunits of MRC complexes, mtDNA depletion will result
in organ dysfunction due to insufficient synthesis of the
respiratory chain components needed for adequate energy
production [5].
The mtDNA depletion syndromes (MDSs) are a het-
erogeneous group of autosomal recessive disorders,
characterized by low mtDNA levels in specific tissues.
These syndromes are a consequence of defects in mtDNA
maintenance caused by mutations in nuclear genes
involved in either nucleotide synthesis (TK2, SUCLA2,
SUCLG1, RRM2B, DGUOK, MPV17 and TYMP) orFigure 1 Schematic view of the mitochondrion and the genes involve
of the genes (namely, POLG and C10orf2-Twinkle) thought to be involved i
be important in the metabolism of the mitochondrial deoxynucleotide (dN
deoxycytidine, deoxytadenine, and deoxiguanosine), and those involved inmtDNA replication (POLG, C10orf2). The first of the
above groups of genes produces proteins that main-
tain the mitochondrial deoxynucleotide triphosphate
(dNTP) pool; dNTPs can be synthesized via either the de
novo pathway (cell cycle-regulated) or the salvage pathway
(in which their production involves the utilization of pre-
existing deoxynucleosides to synthesize DNA precursors).
Given that mtDNA replicates continuously and independ-
ently of cell division, mutations in any of the genes
responsible for maintaining the dNTP pool will result in
mtDNA depletion (Figure 1). Mutations in POLG, the
gene encoding the DNA polymerase gamma (POL γ),
which is required for replication and repair of mtDNA, as
well as mutations in C10orf2 (Twinkle), a mitochondrial
helicase, result in impaired mitochondrial protein synthe-
sis and an incapacity to supply sufficient mtDNA to
daughter cells during cell divisions; this, in turn, leads to a
reduction of mitochondrial genome content [6].
The MDSs are rare, devastating diseases that manifest
typically, although not exclusively, soon after birth, and
usually lead to death in infancy or early childhood.d in mitochondrial depletion syndromes. A “magnifying lens” view
n the replication of mitochondrial DNA (mtDNA), those thought to
TP) pool (via progressive phosphorylation of deoxythymidine,
the tricarboxylic acid cycle and secondary OxPhos involvement.
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specific manner [7], it is not unknown for multiple organs,
including the heart, brain, and kidneys, to be affected [8].
This paper sets out to provide an overview of the clin-
ical manifestations and molecular etiologies of the nuclear
defects involved in MDSs and to offer possible insights for
improving diagnostic strategies.
The mtDNA depletion syndromes – clinical manifestations
The MDSs are usually classified as myopathic, encepha-
lomyopathic, hepatocerebral or neurogastrointestinal [9].
Table 1 summarizes the main clinical manifestations
and molecular etiologies associated with these different
forms.
Hepatocerebral MDS
Hepatocerebral MDS encompasses relatively common
clinical conditions which, to date, have been associated
with over 50 different mutations, including variants in
the POLG, C10orf2, TK2, DGUOK, MPV17 and SUCLG1
genes. Their onset occurs within the first six months of
life and affected subjects usually die within one year of
onset. Common symptoms include persistent vomiting,
failure to thrive, hypotonia and hypoglycemia associated
with progressive neurological deterioration. Histological
changes on liver biopsy include fatty degeneration, bileTable 1 Relative frequency of mutations associated with the
(MDS, source: HGMD Professional database: www.hgmd.cf.ac
Mitochondrial DNA
depletion syndromes
Period
of onset
Clinical features
Hepatocerebral mtDNA
depletion syndrome
Neonatal, early
childhood
Hepatic dysfunction; psychomoto
delay; hypotonia; lactic
acidosis; nystagmus;
neurological dysfunction
Alpers-Huttenlocher
syndrome
Early childhood Hepatic dysfunction; epilepsia
partialis continua; neurological
dysfunction
Myopathic mtDNA
depletion syndrome
Infancy, early
childhood
Hypotonia; muscle weakness;
dysarthria and dysphagia;
failure to thrive
Encephalomyopathic
mtDNA depletion
syndrome
Infancy Hypotonia; muscle weakness;
psychomotor delay; sensorineura
hearing impairment; lactic acidos
neurological dysfunction
Mitochondrial
neurogastrointestinal
encephalomyopathy
Late childhood,
adolescence
Gastrointestinal dysmotility;
weight loss; peripheral
neuropathy;ptosis;
neurological dysfunction
MDS are inherited in an autosomal recessive pattern; mutations in POLG gene outsi
inheritance. *References of the first mutations published associated with the phenoduct proliferation, fibrosis and collapse of lobular archi-
tecture. Reduced cytochome c oxidase (COX) histo-
chemistry and combined deficiency of mtDNA-encoded
MRC complexes have been detected in the livers of
infants and toddlers. A peculiar form of liver failure
occurs in Alpers-Huttenlocher syndrome (AHS), an early-
onset, fatal disease that is, in addition, characterized by
intractable seizures that evolve into epilepsia partialis
continua, and by global neurological deterioration. The
liver dysfunction is usually progressive as well, evolving
from microvesicular steatosis with bile duct proliferation
into cirrhosis and organ failure [25,26]. Brain MRI inclu-
des signal abnormalities in the basal ganglia and thalami,
irregularly widened ventricles and partial pachygyria. Pa-
tients usually present MRC deficiencies and low mtDNA
in the liver, although both these markers may be normal
in skeletal muscle. The prognosis is severe [27].
i) DGUOK
The deoxyguanosine kinase (DGUOK) gene lies on
chromosome 2p13, and codes for a 2-deoxyribonucleoside
enzyme that catalyzes the first step in the mitochondrial
deoxypurine salvage pathway. More specifically, the
DGUOK enzyme catalyzes the phosphorylation of purine
deoxyribonucleosides into the corresponding nucleotides
(deoxyguanosine and deoxyadenosine) necessary for thedifferent mitochondrial DNA depletion syndromes
.uk/)
Genes (aliases) Chromosomal
LOCI
Numbers of
mutations
References*
r POLG (Polg1/PolgA) 15q25 8 [10]
C10orf2 (Twinkle/PEO1) 10q24 3 [11]
DGUOK (dGK) 2p13 51 [12]
MPV17 (SYM1) 2p23.3 28 [13]
TK2 16q22-q23.1 1 [14]
POLG (Polg1/PolgA) 15q25 54 [15]
POLG (Polg1/PolgA) 15q25 1 [5]
TK2 16q22-q23.1 34 [16]
RRM2B (p53R2) 8q23.1 3 [5]
DGUOK (dGK) 2p13 1 [17]
l
is;
RRM2B (p53R2) 8q23.1 14 [18]
TK2 16q22-q23.1 1 [19]
SUCLA2 13q12.2 9 [20]
SUCLG1 2p11.3 13 [21]
TYMP (ECGF1) 22q13 81 [22]
RRM2B (p53R2) 8q23.1 2 [23]
POLG (Polg1/PolgA) 15q25 1 [24]
de MDS may be associated with autosomal recessive/dominant pattern of
type.
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typical phenotype associated with mutations in DGUOK is
neonatal onset of progressive liver disease and feeding
difficulties, usually associated with hypotonia, nystagmus,
and psychomotor retardation by the age of three months.
Most cases harbor null mutations and die before the age
of two years. Peripheral neuropathy and renal tubulo-
pathy have occasionally been reported [29]. Depletion
of mtDNA has been documented mainly in the liver,
where it results in combined reduction of complexes I, III
and IV; the amount of mtDNA is usually normal in other
tissues, at least at disease onset. Histological analyses of
liver biopsies show variable findings, including microvesi-
cular steatosis and cholestasis. Progression is usually rapid
and life expectancy is low [30]. The majority of affected
infants show an elevated serum concentration of tyrosine
or phenylalanine on newborn screening. Intrahepatic cho-
lestasis typically includes elevation of liver transaminases,
gamma-glutamyltransferase and conjugated hyperbiliru-
binemia. An increased serum concentration of ferritin is
often observed [31,32].
Since the initial report of pathogenic mutations in
2001 [12], more than 100 patients have been reported
harboring over 50 different DGUOK mutations (fully
reviewed in [9]).
ii) MPV17
The MPV17 gene is located on chromosome 2p23.3 and
encodes a mitochondrial inner membrane protein whose
function is not yet completely characterized, even
though its key role in controlling mtDNA maintenance
and OxPhos activities in mammals and yeast is well
established [33]. The clinical presentation associated
with mutations in MPV17 consists of severe liver failure,
hypoglycemia, growth retardation, neurological symp-
toms and multiple brain lesions during the first year of
life [34]. Marked liver depletion is found in association
with biochemical deficits, with complex I or complexes
I + III being most affected. Both mildly reduced mtDNA
content and impaired OxPhos activities may also be
noted in muscle [35]. Histological analyses of the liver
have revealed swollen granular hepatocytes, and steatosis
with focal pericellular and periportal fibrosis. More than
30 patients with mutations in MPV17 have been reported
[9], while over 20 different mutations have been described
in infantile-onset hepatocerebral syndrome and also in
Navajo neurohepatopathy, an autosomal recessive multi-
system disorder prevalent in the Navajo community in the
Southwestern United States [28]. There exist three main
subtypes: infantile (onset < 6 months) and childhood
(< 5 years) forms, characterized by hypoglycemic epi-
sodes and severe progressive liver dysfunction requiring
liver transplantation, and a “classic” form characterized by
moderate hepatopathy and progressive motor and sensoryaxonal neuropathy. The three subtypes are also associated
with variable degrees of demyelination in both the central
and the peripheral nervous systems.
iii) POLG
The POLG gene lies on chromosome 15q24 and encodes
POL γ, the only DNA polymerase responsible for mtDNA
replication and repair in mitochondria. POL γ is com-
posed of a catalytic subunit that has both polymerase and
proofreading exonuclease activities, and an accessory
subunit, which increases enzyme processivity [32].
This holoenzyme functions in conjunction with the
mtDNA helicase and the mitochondrial single-stranded
DNA-binding protein to form the minimal replication ap-
paratus [36].
Over 200 mutations have been reported in the POLG
gene (Human DNA Polymerase Gamma Mutation data-
base [37]), making this gene a hot-spot for mutations
associated with mitochondrial diseases [38,39]. Individuals
affected by POLG-related disorders present with a large
variety of clinical phenotypes, ranging from autosomal
dominantly and recessively inherited forms of progressive
external ophthalmoplegia (PEO) to juvenile spinocere-
bellar ataxia and epilepsy with or without dysarthria, and
AHS [27,40].
Approximately 45 different point mutations in POLG
cause AHS [27] whose incidence has been estimated to
be ~1:50,000 [41]. The two most common POLG muta-
tions detected in AHS, i.e., p.Ala467Thr and p.Trp748Ser,
can be either homozygous or heterozygous and can be
present in combination with other variants. Carrier fre-
quency for these mutations is higher in Western countries
than elsewhere. For example, in Finland it is 1:125 for
p.Trp748Ser, in Norway it is 1:50, if both variants are
combined, whereas 0.6% of the control Belgian popu-
lation harbors p.Ala467Thr. A single ancestral founder
mutation is hypothesized for both variants [6].
iv) C10orf2 (Twinkle)
The mitochondrial protein Twinkle, encoded by C10orf2/
PEO1 located on chromosome 10q24, is an mtDNA
helicase, active as a homohexamer and bound to mtDNA
in mitochondrial nucleoids [42]. Mutations in C10orf2
cause dominantly inherited disorders, such as pure adult-
onset PEO with multiple mtDNA deletions, or recessive
clinical conditions including severe early-onset hepato-
encephalopathy or infantile-onset spinocerebellar ataxia
(IOSCA) and low mtDNA in the brain and liver, but not
in skeletal muscle [6]. Neuroimaging can show cortical
cerebellar atrophy; OxPhos assays show reduction of com-
plexes I, III and IV.
Infantile-onset spinocerebellar ataxia is a severe auto-
somal recessive neurodegenerative disorder that manifests
itself after 9-18 months of age through progressive
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ataxia during the first two years of life, hypotonia with
sensory axonal neuropathy, optic atrophy, hearing impair-
ment and ophthalmoplegia [6]. Patients usually survive to
adulthood. The severe neurological phenotype and the ob-
served absence of muscle involvement in IOSCA suggest
that Twinkle may play a crucial role in the maintenance
and function of specific neuronal subpopulations [8].
Infantile-onset spinocerebellar ataxia is the second most
common heritable ataxia in Finland, this high frequency
being due to the founder effect of the p.Tyr508Cys variant
and a carrier frequency of about 1:200. The same muta-
tion has also been described in cases with severe epileptic
encephalopathy and hepatic failure [43].
Myopathic MDS
The symptoms of myopathic MDS usually appear in the
first year of life and consist of feeding difficulties, failure
to thrive, hypotonia, muscle weakness and, occasionally,
PEO. Death is often due to pulmonary insufficiency and
recurrent infections, but some patients survive into their
teens [44]. Muscle biopsy may show proliferation of
mitochondria, and patchy or diffuse deficiency of COX.
Biochemical defects are always present in all mtDNA-
related respiratory chain complexes in muscle mito-
chondria. Serum creatine kinase levels may be variably
elevated [45].
i) TK2
The TK2 gene lies on chromosome 16q22 and encodes
thymidine kinase (TK2). TK2 is an intramitochondrial
pyrimidine nucleoside kinase that phosphorylates dNTPs,
such as deoxythymidine, deoxycytidine and deoxyuridine,
thereby participating in the salvage pathway of deoxynu-
cleotide synthesis [46]. Mitochondrial dNTP pools arise
either through active transport of cytosolic dNTPs or
through salvage pathways. Both pathways are essential for
the replication of mtDNA, since the mitochondrion is
unable to synthesize dNTPs de novo. Mutations in TK2
primarily affect muscle tissue, and have little or no effect
on the liver, brain, heart or skin. The clinical presentation
of TK2-related MDS is variable, with a broad phenotype.
Typical manifestations include a severe, rapidly progres-
sing myopathy of infantile or childhood onset. The disease
course is rapidly progressive, leading to respiratory failure
and death within months or a few years, although milder
phenotypes with slower progression and longer survival
have been described [6]. To date, around 50 individuals
with TK2-related MDS have been reported [9]. Since the
description of the first mutation in 2001 [16], 31 different
pathogenic autosomal recessive mutations have been
described, and the different phenotypes may be explained
by variable degrees of residual activity of the mutant
enzymes. Mutations in POLG and RRM2B are additionaletiologies in myopathic presentations of reduced mito-
chondrial copy number. Milder presentations manifest as
late-onset proximal muscle weakness or adult-onset pro-
gressive myopathy, with or without sensorineural hearing
loss [9].
Encephalomyopathic MDS
Encephalomyopathic MDS embraces phenotypes characterized
by infantile onset of hypotonia with severe psychomotor
retardation, high blood lactate levels, progressive hyperkinetic-
dystonic disorder, external ophthalmoplegia, deafness,
generalized seizures and variable renal tubular dysfunction.
Brain MRI is often abnormal and was initially suggested to
be reminiscent of the pathological features seen in Leigh
syndrome [8].
i) RRM2B
The RRM2B gene lies on chromosome 8q23.1 and codes
for the small subunit of p53-inducible ribonucleotide
reductase, a heterotetrameric enzyme responsible for de
novo conversion of ribonucleoside diphosphates into the
corresponding deoxyribonucleoside diphosphates that
are crucial for DNA synthesis [18]. Ribonucleotide re-
ductase is the main regulator of the nucleotide pools in
the cytoplasm and its small subunit is expressed in post-
mitotic cells, where it probably has a key function in
maintaining the mitochondrial dNTP pools for mtDNA
synthesis. Mutations in RRM2B usually result in neo-
natal hypotonia, lactic acidosis, failure to thrive and
tubulopathy. Psychomotor delay, sensorineural hearing
loss and a profound reduction of mtDNA copy numbers
in skeletal muscle [18] are also present. The disease has
a rapid progression and leads to death within a few months
of onset. The complex associated phenotype suggests that
the consequences of defective mitochondrial dNTP pools
can vary dramatically depending on the residual amount of
functional enzyme. Approximately 15 affected infants have
been described [9]. Of the 31 mutations described to date,
30 are associated with major phenotypes.
ii) SUCLA2 and SUCLG1
Succinyl CoA synthase is a mitochondrial matrix enzyme
that catalyzes the reversible synthesis of succinate and ATP
or GTP from succinyl-CoA and ADP in the tricarboxylic
acid cycle. It is made up of two subunits, alpha and beta,
encoded by SUCLG1 on chromosome 2p11.3 and SUCLA2
on 13q12.2-q13.3, respectively. Mutations in SUCLA2
(coding for succinate-CoA ligase, beta subunit) and
SUCLG1 (coding for succinate-CoA ligase, alpha subunit)
cause an encephalomyopathic form of infantile MDS,
but mutations in SUCLG1 can also cause a severe
disorder characterized by antenatal dysmorphisms,
neonatal metabolic crisis, and early death [47]. Differences
in presentation between patients might depend on
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[20,48,49]. Useful diagnostic clues in succinyl CoA
synthase disorders are the presence of “mildly” elevated
urinary methylmalonic acid, found in all patients, and the
presence of tricarboxylic acid cycle intermediates (methyl-
citrate, lactate, carnitine esters, 3-hydroxyisovalericacid),
found in most cases. Some patients die as infants, but
others survive longer. The clinical features include early
childhood hypotonia, developmental delay and, almost
invariably, progressive dystonia and sensorineural deaf-
ness. Mutations in SUCLA2 and SUCLG1 seem to disrupt
the association between succinyl CoA synthase and
mitochondrial nucleoside diphosphate kinase, resulting in
mitochondrial dNTP pool imbalance and, eventually, low
levels of mtDNA in muscle [21]. Twenty-three mutations
were recently reported in a series of 54 individuals [9]: 10
in the 34 subjects with mutated SUCLA2 and 13 in
the 20 with mutated SUCLG1.Neurogastrointestinal MDS
Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) is an autosomal recessive disorder clinically
characterized by onset between the first and fifth de-
cades of life, although in the vast majority of cases onset
occurs before the age of 20 years. All affected individuals
develop weight loss and progressive gastrointestinal
dysmotility manifesting as early satiety, nausea, dys-
phagia, gastroesophageal reflux, postprandial emesis,
episodic abdominal pain with distention, and diarrhea.
In addition, all affected individuals have motor and sen-
sory demyelinating neuropathy, in some cases accompan-
ied by axonal neuropathy. The neuropathy typically
presents with distal weakness and paresthesias, showing a
symmetric stocking-glove distribution. Ptosis and ophthal-
moplegia are common.
Affected individuals can have elevated CSF protein
and plasma lactate. Thymidine and deoxyuridine are
increased in plasma. Thymidine phosphorylase (TP)
enzyme activity in leukocytes is usually less than 10% of
the control mean. Neuroimaging typically demonstrates
diffuse white matter changes [9].
In MNGIE, mtDNA abnormalities can include deple-
tion, multiple deletions and point mutations [50]. Muta-
tions in TYMP and RRM2B have been linked to MNGIE,
although variants in POLG have recently been detected in
conditions mimicking MNGIE (so-called MNGIE-like
syndromes) [24].
Skeletal muscle generally shows ragged-red fibers and
defects in single or multiple OxPhos complexes, espe-
cially COX. However, MNGIE has also been reported
without morphological, enzymatic, or mtDNA changes
in skeletal muscle. Life expectancy is reduced (ranging
from 25–60 years) [9].i) TYMP
The TYMP gene is located on chromosome 22q13
and encodes the cytosolic TP enzyme, which catalyzes
the conversion of thymidine to thymine and of deox-
yuridine to uracil and is therefore essential for pyrimidine
catabolism. TP deficiency causes systemic accumulation of
thymidine and deoxyuridine; this leads to deoxynucleotide
pool imbalance and mtDNA instability, in turn resulting
in the presence of multiple deletions and partial depletion
of muscle mtDNA [22].
The first pathogenic mutations in the TYMP gene
were described in 1999 [22] and since then over 70
mutations have been described, most associated with
MNGIE.
MDS - diagnostic approaches
The suspicion of MDS is usually based on the clinical
presentation, which may range from well-defined syn-
dromes to non-specific multisystem phenotypes, and
usually includes neurological involvement. Establishing a
specific MDS diagnosis is challenging and requires the
integration of clinical assessments, family history, bio-
chemical testing and histopathological examination in
affected tissues. It is important to obtain the appropriate
biochemical and clinical information before starting any
molecular investigations in order to increase the chances
of a successful molecular diagnosis. Biochemical deter-
mination of MRC complexes is also important, although
the results can be normal if skeletal muscle is not among
the affected tissues. Quantitative real-time PCR quantifi-
cation of total mtDNA content in affected tissues, using
a nuclear gene as reference, is a prerequisite for correct
interpretation of the amount of mtDNA present, al-
though it is important, given the dynamic nature of
mtDNA copies in different ages and tissues, to select
appropriate age-matched control materials [51]. A re-
duction in mtDNA copy number to 60-65% of the aver-
age recorded in age-matched controls is the empirical
cut-off level for a diagnosis of primary MDS. However,
the reduction could be even greater, with mtDNA levels
in most patients being about 20-25% of age-matched
normal controls. Biochemical data, such as lactate, pyru-
vate, alanine and organic acid profiles, as well as neuro-
imaging findings, are also important diagnostic clues.
Serum CK is elevated particularly when mutations occur
in TK2; serum thymidine is impaired in TYMP, and
mildly elevated levels of urinary methylmalonic acid and
methylcitrate occur in disorders linked to SUCLA2 or
SUCLG1 [6]. Figure 2 summarizes the diagnostic algorithm
in syndromes associated with mitochondrial DNA de-
pletion. Reaching a full molecular characterization is
also important for adopting appropriate therapies:
the detection of changes in POLG and C10orf2 in
toddlers with severe drug-resistant epilepsy should
Figure 2 Diagnostic algorithm for mitochondrial depletion syndromes, based on clinical and biochemical information. Abbreviations:
MDS- mitochondrial depletion syndrome; CK- creatine kinase; MNGIE- mitochondrial neurogastroIntestinal encephalomyopathy; qPCR - real-time
PCR; SB- Southern blot.
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induced liver toxicity [52].
MDS - therapeutic considerations
The management of mitochondrial diseases is largely
supportive, given that there exists no “magic pill” [53].
Palliative treatments with vitamins, cofactors and respira-
tory substrates have been used, but they showed poor
efficacy. In recent years several approaches have been
adopted, mostly involving modulation of the different
pathways regulating mitochondrial biogenesis [39], butthey have yet to be applied in the clinic. Meanwhile, some
therapeutic avenues have been tried in clinical practice,
although none has shown evidence-based efficacy.
Liver transplantation may be beneficial to patients with
hepatopathy caused by DGUOK mutations if no neuro-
logical symptoms have developed. However, it would be
contraindicated in the presence of significant hypotonia,
psychomotor retardation or nystagmus [31]. In patients
with MPV17, and in VPA-induced organ failure, trans-
plantation has increased quality of life and life expectancy
in some patients [5,54], but liver-transplanted children
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controlled diet, avoiding hypoglycemia, has been proposed
to slow down disease progression and allow supportive care
[57]. Some improvement was suggested with succinate or
coenzyme Q10 together with a lipid-rich diet [58]. Further-
more, folate levels may be deficient in the CSF of some
patients and detection of low folate in the CSF may prompt
replacement therapy [59]. Levocarnitine, creatine mono-
hydrate, coenzyme Q10, B vitamins, and antioxidants, such
as alpha lipoic acid, vitamin E, and vitamin C, have often
been used as pro-energy supplements in mitochondrial
disorders in general and in MDS in particular, but longer
follow-ups are necessary to evaluate the opportuneness of
recommending such dietary interventions [53]. In MNGIE,
a correlation between plasma thymidine levels and the
severity of the phenotype has been observed [60]. There-
fore, attempts to reduce the circulating nucleotide levels
could result in disease improvement. Enzyme replacement
therapy has been used in MNGIE: infusions of platelets
from healthy donors reduced circulating thymidine and
deoxyuracile levels and partially restored TP activity. The
limitation of this therapy was the short half-life of the
platelets [61]. Allogeneic stem cell transfusions have been
given to two patients with MNGIE [62,63]; although more
experience is needed to illustrate the clinical benefit of this
treatment, it opens up a therapeutic possibility for disorders
of nucleoside metabolism. Finally, continuous ambula-
tory peritoneal dialysis has also been used in MNGIE
to reduce thymidine levels, and this treatment improved
symptoms during a three-year follow-up [64].
Concluding remarks
A mitochondrial disease manifesting at, or soon after,
birth is more likely to be associated with nDNA than
with mtDNA mutations [39], but until very recently our
ignorance regarding the mechanisms underlying mito-
chondrial gene transcription and translation and the
complex interaction between the “two genomes” limited
our diagnostic power.
Mitochondrial DNA depletion, which can result from
any imbalance in the mitochondrial nucleotide pool avail-
able for mtDNA replication, as well as abnormalities in
mitochondrial replication machinery, has become an in-
creasingly important cause of a wide spectrum of infantile
and childhood-onset tissue-specific and multisystem
disorders [65]. Consistent with the different phenotypes,
mtDNA depletion may affect a specific tissue type (most
commonly brain and muscle or liver tissue) or multiple
organs, including the heart and kidneys. More than 75%
of MDS patients develop full-blown disease within the
first year of life, and it is rapidly fatal in most cases
[11,66]. Identifying the causative genes is important not
only to allow adequate antenatal options, family planning
and prenatal diagnosis, but also to improve understandingof the disease pathophysiology and, therefore, improve
therapeutic options. From this perspective, the recent
advances in the clinical use of next generation sequencing
(NGS) technologies will likely facilitate molecular diagno-
sis of these conditions in the coming years [67-69]. Since
NGS is becoming a feasible option in several Mendelian
disorders and inborn errors of metabolism [70], it promises
to allow the identification of a greater number of patients
with mitochondrial disorders as well [71,72]. This would
likely resolve some of the open issues emerging from
clinical practice in this field, which include difficulties in
diagnosing the conditions and in providing adequate
counseling, and unpredictable prognoses. An accurate and
focused diagnostic workup would also save health-related
resources and family distress. Only by achieving a full
understanding of the molecular basis of MDS will we be
able to gather insights for novel and effective therapeutic
strategies.
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